- Focused on discovering new technologies that deliver cannabinoids and other beneficial molecules to the bloodstream
- Bypassing the negative side effects of lighting up
- Crossing blood brain barrier
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is focused on discovering new technologies that deliver cannabinoids and other lipophilic (fat soluble) beneficial molecules to the bloodstream through efficient and healthy ingestion.
The first step to discovering how to deliver a higher percentage into the human bloodstream was to find a way to protect the molecules on their journey through the gastrointestinal system. It was discovered that fats are an excellent conduit, increasing absorption and breaking down molecules into more easily absorbed particles in the small intestine, bypassing the liver. Lexaria’s DehydraTECH drug delivery platform manipulates CBD and other beneficial molecules in certain ways to connect them at a molecular level with various foods, including but not limited to fatty foods.
With the increased understanding of bioavailability, DehydraTECH is providing an alternative to smoking. The edible technology holds promise that the negative side effects of lighting up can be bypassed with a more effective delivery mechanism for cannabinoids, nicotine, pain relievers, vitamins, supplements and more. The technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream and improved taste and smell.
Lexaria Nicotine Corp, a wholly owned subsidiary, is working to encourage cigarette smokers to use alternative forms of nicotine that do not lead to lung cancer. By promoting healthier ingestion methods while providing lower overall dosing, Lexaria is at an advantage as the FDA pushes for improved public health through the reduction of nicotine consumption.
In a press release from August 2018, Lexaria announced a second-generation study in 40 rats. The study resulted in Lexaria’s formulation being four-times faster at reaching its peak level in brain tissue than the non-enhanced control formulation. In a press release (http://ibn.fm/yYhZk), Chris Bunka, chief executive officer of Lexaria, stated, “DehydraTECH delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the need for combustion or the need for inhalation whatsoever. Crossing the blood brain barrier is a significant achievement all on its own and this data confirms the outcome of our earlier first-generation test.”
This technology could also hold promise for application of treatment of nervous system diseases, such as Alzheimer’s and Parkinson’s. Crossing the blood-brain barrier is significant beyond its applications to nicotine. The similarities in physical structure between the nicotine molecule and several of the drugs used to treat nervous system diseases mean that Lexaria is strategically poised to change the efficiency of drug delivery across multiple channels.
Currently, Lexaria is the only company in the world with a patent for the improved (oral or ingestible, including pills) delivery of all non-psychoactive cannabinoids and has patents pending in over 40 countries.
For more information, visit the company’s website at www.LexariaBioscience.com
